Nascent Biotech Inc
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing Multi… Read more
Market Cap & Net Worth: Nascent Biotech Inc (NBIO)
Nascent Biotech Inc (OTCQB:NBIO) has a market capitalization of $1.12 Million ($1.12 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #42230 globally and #13676 in its home market, demonstrating a 44.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nascent Biotech Inc's stock price $0.01 by its total outstanding shares 172217165 (172.22 Million).
Nascent Biotech Inc Market Cap History: 2015 to 2025
Nascent Biotech Inc's market capitalization history from 2015 to 2025. Data shows change from $31.00 Million to $1.12 Million (-30.73% CAGR).
Nascent Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nascent Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
34.44x
Nascent Biotech Inc's market cap is 34.44 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $30.86 Million | $3.00 Million | $1.14 Million | 10.29x | 27.14x |
| 2021 | $8.78 Million | $750.00K | -$958.77K | 11.71x | N/A |
| 2022 | $34.44 Million | $1.00 Million | -$470.39K | 34.44x | N/A |
Competitor Companies of NBIO by Market Capitalization
Companies near Nascent Biotech Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Nascent Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Nascent Biotech Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Nascent Biotech Inc's market cap moved from $31.00 Million to $ 1.12 Million, with a yearly change of -30.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.12 Million | -89.48% |
| 2024 | $10.64 Million | -64.26% |
| 2023 | $29.78 Million | -13.55% |
| 2022 | $34.44 Million | +292.16% |
| 2021 | $8.78 Million | +10.63% |
| 2020 | $7.94 Million | -53.90% |
| 2019 | $17.22 Million | -41.18% |
| 2018 | $29.28 Million | -5.13% |
| 2017 | $30.86 Million | -28.32% |
| 2016 | $43.05 Million | +38.89% |
| 2015 | $31.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Nascent Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.12 Million USD |
| MoneyControl | $1.12 Million USD |
| MarketWatch | $1.12 Million USD |
| marketcap.company | $1.12 Million USD |
| Reuters | $1.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.